Edition:
United States

Mylan NV (MYL.O)

MYL.O on Nasdaq

37.28USD
22 Nov 2017
Change (% chg)

$0.05 (+0.13%)
Prev Close
$37.23
Open
$37.11
Day's High
$37.76
Day's Low
$36.99
Volume
3,324,696
Avg. Vol
6,601,309
52-wk High
$45.87
52-wk Low
$29.39

Chart for

About

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic, brand name and over-the-counter (OTC) products in a range of dosage forms and therapeutic categories. It operates through three segments on a geographic basis, North America, Europe and Rest of World. The... (more)

Overall

Beta: 1.39
Market Cap(Mil.): $19,992.55
Shares Outstanding(Mil.): 536.28
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.56 15.47
EPS (TTM): -- -- --
ROI: -- 15.17 11.81
ROE: -- 16.58 15.76

BRIEF-Theravance Biopharma and Mylan submit marketing application to FDA for revefenacin

* Theravance Biopharma and Mylan submit new drug application to FDA for revefenacin (TD-4208) in adults with chronic obstructive pulmonary disease

Nov 13 2017

BRIEF-Mylan announces voluntary delisting from the Tel Aviv Stock Exchange (TASE)

* Mylan announces voluntary delisting from the Tel Aviv Stock Exchange (TASE)

Nov 10 2017

BRIEF-Mylan launches generic Clolar for injection

* Mylan launches generic Clolar for injection Source text for Eikon: Further company coverage:

Nov 09 2017

BRIEF-Biocon says Mylan resubmits Biosimilar Trastuzumab and Pegfilgrastim dosseirs with EMA‍​

* Says mylan resubmits Biosimilar Trastuzumab and Pegfilgrastim dosseirs with EMA‍​ Source text for Eikon: Further company coverage:

Nov 06 2017

Mylan raises forecast on strength of generic Copaxone

Mylan NV on Monday raised its full-year forecast and expects sales from its recently approved version of Teva's blockbuster multiple sclerosis treatment Copaxone to offset declining revenue from its EpiPen emergency allergy injector.

Nov 06 2017

UPDATE 3-Mylan raises forecast on strength of generic Copaxone

* Raises lower end of 2017 revenue, adjusts earnings forecasts

Nov 06 2017

Drugmaker Mylan's revenue drops 2.3 percent

Nov 6 U.S. drugmaker Mylan NV reported a 2.3 percent decline in third-quarter revenue on Monday, hurt by lower sales in North America.

Nov 06 2017

BRIEF-Momenta Pharma says Q3 loss per share $0.44

* Momenta Pharmaceuticals reports third quarter 2017 financial results and provides corporate update

Nov 01 2017

BRIEF-Theravance Biopharma and Mylan reports positive Phase 3 data for Revefenacin

* Theravance Biopharma and mylan report additional positive phase 3 data for Revefenacin (TD-4208) in multiple presentations at 2017 Chest Annual Meeting

Nov 01 2017

BRIEF-Momenta And Mylan report initial results from phase 1 clinical trial for M834

* Momenta And Mylan report initial results from phase 1 clinical trial for M834, a proposed biosimilar of Orencia® (abatacept)

Nov 01 2017

Earnings vs. Estimates